ACADIA Q4 Sales Surge to $284M, Guides $1.22–1.28B 2026 Revenue, Wolfe Sets $33 Target
ACADIA reported Q4 GAAP revenues of $284M and FY25 GAAP revenues of $1.07B, with Q4 non-GAAP sales of $298M and full-year non-GAAP revenues of $1.08B. It projects FY26 revenues of $1.22–1.28B from NUPLAZID ($760–790M) and DAYBUE ($460–490M), and received an Outperform rating with a $33 target.
1. Q4 and FY25 Financial Results
ACADIA posted Q4 GAAP revenues of $284 million, up 9% year-over-year, with non-GAAP sales of $298 million. Full-year GAAP revenues reached $1.07 billion, a 12% increase, and non-GAAP revenues hit $1.08 billion, up 16%.
2. 2026 Revenue Guidance
The company forecasts fiscal 2026 revenues of $1.22–1.28 billion, based on projected NUPLAZID sales of $760–790 million and DAYBUE sales of $460–490 million, reflecting continued demand for its key therapies.
3. Wolfe Research Initiation
Wolfe Research initiated coverage with an Outperform rating and a $33 price target, highlighting ACADIA’s conviction-driven portfolio in neuroscience and deeming current valuations for Daybue and NUPLAZID attractive relative to share price.